The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015

Acta Pharmaceutica Sinica B

Volumn 6, Issue 6, 2016, Pages 522-530

  Chen, Xiaoling ^a   Wang, Kewei ^a,b  

^a PEKING UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Ion channel; Ischemic stroke; Neuroprotective agent; Non NMDA mechanism; Thrombosis; Traditional Chinese medicine

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS HYDROCHLOROTHIAZIDE PLUS RAMIPRIL PLUS SIMVASTATIN; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; APIXABAN; ATENOLOL; BORNEOL; CEREBROLYSIN; CILOSTAZOL; CITICOLINE; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FASUDIL; GINGKO MIHUAN EXTRACT; HYDROCHLOROTHIAZIDE; KALLIKREIN; LUMBRICUS RUBELLUS EXTRACT; NEUROPROTECTIVE AGENT; NORPHENAZONE; PLANT EXTRACT; RAMIPRIL; RETEPLASE; RIVAROXABAN; SIMVASTATIN; TENECTEPLASE; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCITOTOXICITY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; THROMBOCYTE AGGREGATION;

EID: 84995308974     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2016.06.013     Document Type: Review

References (64)

1. 1 Wang, L.D., Report on the Chinese stroke prevention, 2015, Pecking Union Medical College Press, Beijing.
2. 2 Liu, L., Wang, D., Wong, K.S., Wang, Y., Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 42 (2011), 3651–3654.
3. 3 Liu, M., Wu, B., Wang, W.Z., Lee, L.M., Zhang, S.H., Kong, L.Z., Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 6 (2007), 456–464.
4. 4 Wang, Y.L., Zhao, X.Q., Jiang, Y., Li, H., Wang, L.M., Johnston, S.C., et al. Prevalence, knowledge, and treatment of transient ischemic attacks in China. Neurology 84 (2015), 2354–2361.
5. 5 Wu, X.M., Zhu, B., Fu, L.Y., Wang, H.L., Zhou, B., Zou, S.F., et al. Prevalence, incidence, and mortality of stroke in the chinese island populations: a systematic review. PLoS One, 8, 2013, e78629.
6. 6 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2016 update: a report from the american heart association. Circulation 133 (2016), e38–e60.
7. 7 Casson, R.J., Chidlow, G., Ebneter, A., Wood, J.P., Crowston, J., Goldberg, I., Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin Exp Ophthalmol 40 (2012), 350–357.
8. 8 Seidl, S.E., Potashkin, J.A., The promise of neuroprotective agents in Parkinson׳s disease. Front Neurol, 2, 2011, 68.
9. 9 Guyot, L.L., Diaz, F.G., O׳Regan, M.H., McLeod, S., Park, H., Phillis, J.W., Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 299 (2001), 37–40.
10. 10 Miljanich, G.P., Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11 (2004), 3029–3040.
11. 11 Heading, C.E., Ziconotide (Elan Pharmaceuticals). IDrugs 4 (2001), 339–350.
12. 12 Lipton, S.A., Rosenberg, P.A., Excitatory amino acids as a final common pathway for neurologic disorders. New Eng J Med 330 (1994), 613–622.
13. 13 Muir, K.W., Lees, K.R., Clinical experience with excitatory amino acid antagonist drugs. Stroke 26 (1995), 503–513.
14. 14 Grotta, J., Clark, W., Coull, B., Pettigrew, L.C., Mackay, B., Goldstein, L.B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 26 (1995), 602–605.
15. 15 Stewart, L., Bullock, R., Teasdale, G.M., Wagstaff, A., First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury. J Neurotrauma 16 (1999), 843–850.
16. 16 Davis, S.M., Lees, K.R., Albers, G.W., Diener, H.C., Markabi, S., Karlsson, G., et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31 (2000), 347–354.
17. 17 Chan, P.H., The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Editorial Comment. Stroke, 31, 2000, 1714.
18. 18 Schabitz, W.R., Li, F.H., Fisher, M., The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke 31 (2000), 1709–1714.
19. 19 Albers, G.W., Goldstein, L.B., Hall, D., Lesko, L.M., Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. J Am Med Assoc 286 (2001), 2673–2682.
20. 20 Turski, L., Huth, A., Sheardown, M., McDonald, F., Neuhaus, R., Schneider, H.H., et al. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A 95 (1998), 10960–10965.
21. 21 Walters, M.R., Kaste, M., Lees, K.R., Diener, H.C., Hommel, M., De Keyser, J., et al. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis 20 (2005), 304–309.
22. 22 Terai, K., Suzuki, M., Sasamata, M., Yatsugi, S.I., Yamaguchi, T., Miyata, K., Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol 467 (2003), 95–101.
23. 23 Ikonomidou, C., Turski, L., Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lan Neurol 1 (2002), 383–386.
24. 24 O׳Bryant, Z., Vann, K.T., Xiong, Z.G., Translational strategies for neuroprotection in ischemic stroke—focusing on acid-sensing ion channel 1a. Transl Stroke Res 5 (2014), 59–68.
25. 25 Leng, T.D., Shi, Y.J., Xiong, Z.G., Sun, D.D., Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke?. Prog Neurobiol 115 (2014), 189–209.
26. 26 Zhang, E., Liao, P., Brain transient receptor potential channels and stroke. J Neurosci Res 93 (2015), 1165–1183.
27. 27 Romero, J.R., Ridker, P.M., Zee, R.Y., Gene variation of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7), and risk of incident ischemic stroke: prospective, nested, case-control study. Stroke 40 (2009), 2965–2968.
28. 28 Gelderblom, M., Melzer, N., Schattling, B., Göb, E., Hicking, G., Arunachalam, P., et al. Transient receptor potential melastatin subfamily member 2 cation channel regulates detrimental immune cell invasion in ischemic stroke. Stroke 45 (2014), 3395–3402.
29. 29 Xu, X.S., Wang, P.J., Zhao, Z.G., Cao, T.B., He, H.B., Luo, Z.D., et al. Activation of transient receptor potential vanilloid 1 by dietary capsaicin delays the onset of stroke in stroke-prone spontaneously hypertensive rats. Stroke 42 (2011), 3245–3251.
30. 30 Simard, J.M., Tarasov, K.V., Gerzanich, V., Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta 1772 (2007), 947–957.
31. 31 ClinicalTrials. gov [Internet]. China: compound edaravone injection for acute ischemic stroke. A multi-center, randomized, double-blind, multi-dose, parallel, and controlled phase II trial. [updated 01.07.15]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01929096?term=NCT01929096&rank=1〉.
32. 32 ClinicalTrials. gov [Internet]. China: compound edaravone injection for acute ischemic stroke. A multi-center, randomized, double-blind, parallel, and active-controlled phase III trial. [updated 19.04.16]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT02430350?term=NCT02430350&rank=1〉.
33. 33 Verstraete, M., Third-generation thrombolytic drugs. Am J Med 109 (2000), 52–58.
34. 34 Hudson, I., Alteplase for ischaemic stroke–responses. Lancet 384 (2014), 662–663.
35. 35 Emberson, J., Lees, K.R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
36. 36 Sandercock, P., Wardlaw, J.M., Lindley, R.I., Dennis, M., Cohen, G., Murray, G., et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379 (2012), 2352–2363.
37. 37 Wardlaw, J., Dennis, M., Cohen, G., Murray, G., Innes, K., Whiteley, M., et al. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol 12 (2013), 768–776.
38. 38 Wisløff, T., Hagen, G., Klemp, M., Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics 32 (2014), 601–612.
39. 39 Rognoni, C., Marchetti, M., Quaglini, S., Liberato, N.L., Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig 34 (2014), 9–17.
40. 40 Halvorsen, S., Atar, D., Yang, H.Q., De Caterina, R., Erol, C., Garcia, D., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35 (2014), 1864–1872.
41. 41 Goto, S., Zhu, J., Liu, L.S., Oh, B.H., Wojdyla, D.M., Aylward, P., et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J 168 (2014), 303–309.
42. 42 Wallentin, L., Lopes, R.D., Hanna, M., Thomas, L., Hellkamp, A., Nepal, S., et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127 (2013), 2166–2176.
43. 43 Urquhart, J., The indian polycap study (TIPS). Lancet 374 (2009), 781–782.
44. 44 Indian Polycap Study, Yusuf, S., Pais, P., Afzal, R., Xavier, D., Teo, K., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373 (2009), 1341–1351.
45. 45 Jeyaseelan, K., Lim, K.Y., Armugam, A., Neuroprotectants in stroke therapy. Expert Opin Pharmacother 9 (2008), 887–900.
46. 46 Trisina, J., Sunardi, F., Suhartono, M.T., Tjandrawinata, R.R., DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities. J Biomed Biotechnol, 2011, 2011, 519652.
47. 47 ClinicalTrials. gov [Internet]. Indonesia: the role of DLBS1033 in evaluating bleeding profile and clinical outcome in patients with acute ischemic stroke: comparison with aspirin and clopidogrel. [updated 03.06.14]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01790997?term=NCT01790997&rank=1〉.
48. 48 ClinicalTrials. gov [Internet]. Indonesia: addition of DLBS1033 to standard therapy for acute ischemic stroke patients; [updated 13.06.16]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT02133521?term=NCT02133521&rank=1〉.
49. 49 Zhang, T., Yan, W.H., Li, Q., Fu, J.L., Liu, K.Y., Jia, W.P., et al. 3-n-Butylphthalide (NBP) attenuated neuronal autophagy and amyloid-β expression in diabetic mice subjected to brain ischemia. Neurol Res 33 (2011), 396–404.
50. 50 Ji, X.C., Zhao, W.H., Cao, D.X., Shi, Q.Q., Wang, X.L., Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1. Acta Pharmacol Sin 32 (2011), 182–187.
51. 51 ClinicalTrials. gov [Internet]. China: the impact of NBP on the collateral circulation in ICAM1 occlusion (INCIMO). [updated 17.04.16]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT02594995?term=NBP&rank=1〉.
52. 52 Ding, J., Li, Q.Y., Yu, J.Z., Wang, X., Sun, C.H., Lu, C.Z., et al. Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. Mol Cell Neurosci 43 (2010), 201–208.
53. 53 Okamura, N., Saito, M., Mori, A., Sakamoto, K., Kametaka, S., Nakahara, T., et al. Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther 23 (2007), 207–212.
54. 54 Liu, Y.H., Zhao, Y., Huang, F.Z., Chen, Y.H., Wang, H.X., Bonney, E., et al. Combination of early constraint–induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. Int J Neurosci 126 (2016), 168–173.
55. 2+-permeable acid-sensing ion channel 1a on focal cerebral ischemia in diabetic rats. Int J Clin Exp Pathol 8 (2015), 13255–13260.
56. 56 Menon, P.K., Muresanu, D.F., Sharma, A., Mössler, H., Sharma, H.S., Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 11 (2012), 40–49.
57. 57 Zhang, C.L., Chopp, M., Cui, Y.S., Wang, L., Zhang, R.L., Zhang, L., et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 88 (2010), 3275–3281.
58. 58 Ziganshina, L.E., Abakumova, T., Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev, 2015, 6 CD007026.
59. 59 Ziganshina, L.E., Abakumova, T., Kuchaeva, A., Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev, 2010, 14 CD007026.
60. 60 Rao, A.M., Hatcher, J.F., Dempsey, R.J., CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res 58 (1999), 697–705.
61. 61 Dávalos, A., Alvarez-Sabín, J., Castillo, J., Díez-Tejedor, E., Ferro, J., Martínez-Vila, E., et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380 (2012), 349–357.
62. 62 Alberts, M.J., ACP journal club. Citicoline did not improve recovery at 90 days after moderate-to-severe acute ischemic stroke. Ann Intern Med 157 (2012), JC3–13.
63. 63 Xia, C.F., Yin, H., Yao, Y.Y., Borlongan, C.V., Chao, L., Chao, J.L., Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 17 (2006), 206–219.
64. 64 Zhang, C.F., Tao, W.D., Liu, M., Wang, D.R., Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: a systematic review. J Evid Based Med 5 (2012), 31–39.